Medical Devices & Technology

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced the expansion of its Excelsius™ navigation capabilities with the introduction of DuraPro™, a next-generation oscillating system designed to enhance surgical precision while safeguarding delicate tissue. As part of the company’s Power Portfolio, DuraPro™ aims to optimize procedural workflows by combining advanced oscillating technology with integrated navigation.

Advancing the High-Speed Drill Market with Next-Generation Oscillation

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.

Strategic Response to Market Valuation Trends

SHERIDAN, WYOMING – July 21, 2025 – KaVo Dental has launched the DIAGNOcam Vision Full HD, an innovative dental diagnostic device that enables simultaneous capture, presentation, and storage of three diagnostic images in less than one second. Designed to integrate seamlessly into existing clinical workflows, this advanced system supports dental professionals in enhancing diagnostic accuracy while improving patient communication and care.

Revolutionizing Dental Diagnostics with Real-Time Triple Imaging

With the introduction of the DIAGNOcam Vision Full HD, KaVo Dental brings a significant technological advancement to the dental sector. The device combines cutting-edge transillumination and fluorescence technology, allowing for high-definition, radiation-free imaging that supports early caries detection and more effective patient consultations.

Key features of the DIAGNOcam Vision Full HD include:

SHERIDAN, WYOMING – July 21, 2025 – KaVo has introduced the SURGmatic™ S15 L Pro high-speed contra-angle surgical handpiece, positioning itself at the forefront of surgical innovation with a product designed to meet a broad spectrum of clinical demands. Engineered for both surgical and non-surgical applications, the SURGmatic S15 L Pro underscores KaVo’s commitment to performance, reliability, and operator efficiency in demanding clinical environments.

Enhanced Performance for Complex Surgical Applications

With a gear ratio of 1:5 and rotational speeds reaching up to 200,000 rpm, the SURGmatic S15 L Pro is tailored for procedures requiring precision and power. According to KaVo, this capability enables clinicians to operate effectively even during the most challenging interventions — a strategic advantage in fast-paced surgical settings.

Key features of the SURGmatic S15 L Pro include:

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

This joint initiative is poised to establish SBX as a clinical mainstay in neonatal intensive care units (NICUs), helping identify genetic disorders in newborns with unprecedented speed and precision. It also positions both organizations to lead in delivering fast, scalable, and cost-efficient genomic insights that could redefine diagnostic and therapeutic practices.

Targeting Transformational Impact in Clinical Genomics

SHERIDAN, WYOMING – May 27, 2025 – Roche has received FDA approval for Susvimo® (ranibizumab injection) 100 mg/mL as a new treatment for diabetic retinopathy (DR), marking a pivotal advancement in the battle against this vision-threatening condition that affects nearly 10 million Americans.

The approval makes Susvimo the first and only FDA-approved continuous drug delivery system for DR, offering patients the potential to maintain vision with just one refill every nine months. This development adds a third approved indication for Susvimo, which is already cleared for neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema.

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips has announced the European launch of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter, marking a significant step in transforming structural heart procedures through minimally invasive, real-time imaging technology. Already established in the U.S. market, this cutting-edge device supports more efficient, patient-friendly interventions without requiring general anesthesia — a major development for healthcare providers facing rising demands in structural heart disease care.

Revolutionizing Intracardiac Imaging and Clinical Workflows

VeriSight Pro introduces a miniaturized ultrasound probe at the tip of a steerable catheter, just 3 millimeters in diameter, enabling detailed 2D and 3D imaging directly inside the heart. This innovation allows physicians to perform complex interventions with increased confidence, streamlined workflows, and reduced procedural burden.

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful pricing of a €1 billion dual-tranche bond issuance under its European Medium Term Note (EMTN) program, marking a strategic step to reinforce its capital structure and advance sustainable investment goals.

The offering consists of €500 million in fixed-rate notes due 2030 and another €500 million in notes due 2035. This financial move is designed to refinance existing 2026 debt maturities and fund eligible green projects as defined in the company’s Sustainable Finance Framework. With significant investor interest, both tranches were heavily oversubscribed—by more than three times for the 2030 notes and more than four times for the 2035 notes—underscoring strong market confidence in Philips’ long-term strategy and ESG commitments.

Strategic Financial Optimization with ESG Integration

SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation is reinforcing its position at the forefront of life sciences and diagnostics innovation through its Beacon program—an initiative designed to transform cutting-edge academic research into scalable, market-ready solutions. Spearheaded by Vanessa Almendro, PhD, MBA, Vice President, Head of Science and Technology Innovation at Danaher, the Beacon model exemplifies how strategic academic-industry collaboration can generate high-impact innovations aligned with real-world healthcare and biotechnology challenges.

A Structured Pathway from Discovery to Deployment

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a global leader in medical technology, announced strong first-quarter 2025 results today, demonstrating continued growth and operational efficiency. The company reported high single-digit revenue growth, including double-digit organic revenue increases, as well as expanding operating margins. LivaNova also raised its full-year 2025 revenue guidance, taking into account the impact of the SNIA environmental liability and current tariffs.

Strong Financial Performance in Q1 2025

For the first quarter of 2025, LivaNova recorded total revenue of $316.9 million, a 7.4% increase compared to the same period in 2024. On a constant-currency basis, revenue grew by 8.9%, with organic revenue expanding by 10.4%. Key drivers of growth included strong demand in the Cardiopulmonary and Neuromodulation segments, as well as increased sales from the Essenz™ Perfusion System and cardiopulmonary consumables.